TECH vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

TECH

52.0
AI Score
VS
TECH Wins

MRNA

34.0
AI Score

Investment Advisor Scores

TECH

Nov 11, 2026
52score
Recommendation
HOLD

MRNA

Nov 11, 2026
34score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric TECH MRNA Winner
Forward P/E 35.7143 23.0415 MRNA
PEG Ratio 2.1764 0 Tie
Revenue Growth 4.6% 29.2% MRNA
Earnings Growth -25.0% -85.1% TECH
Tradestie Score 52.0/100 34.0/100 TECH
Profit Margin 14.0% -110.5% TECH
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation HOLD AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

TECH 1M: +0.4% · 3M: +0.9% MRNA 1M: +15.0% · 3M: +290.7%

Current Technical Phase

TECH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 60

RSI (14): 60.4 · Price: $72.80

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (34.1% over 20 days), RSI 59

RSI (14): 58.9 · Price: $248.69

Fundamentals Snapshot

Metric TECH MRNA
Market Cap — —
Forward P/E 42.8 -56.5
Trailing P/E 66.8 —
Revenue (TTM) — —
Revenue Growth 0.0% 0.3%
Gross Margin 0.7% -0.4%
Operating Margin 0.1% 0.1%
EPS 1.09 -6.56
Dividend Yield 0.00% —

Frequently Asked Questions

Based on our detailed analysis, TECH is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.